Similar articles for PMID: 26372949

Year	Number of Results
2004	1
2006	1
2008	1
2012	1
2013	1
2014	7
2015	12
2016	13
2017	12
2018	12
2019	12
2020	10
2021	5
2022	6
2024	0

1

New Advances in the Treatment of Metastatic Pancreatic Cancer.

Schober M, Javed MA, Beyer G, Le N, Vinci A, Sund M, Neesse A, Krug S. Schober M, et al. Digestion. 2015;92(3):175-84. doi: 10.1159/000439523. Digestion. 2015. PMID: 26372949 Free article. Review.

2

Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.

Gbolahan OB, Tong Y, Sehdev A, O'Neil B, Shahda S. Gbolahan OB, et al. BMC Cancer. 2019 May 17;19(1):468. doi: 10.1186/s12885-019-5630-4. BMC Cancer. 2019. PMID: 31101022 Free PMC article.

3

Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.

Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D'Andrea MR. Giordano G, et al. World J Gastroenterol. 2017 Aug 28;23(32):5875-5886. doi: 10.3748/wjg.v23.i32.5875. World J Gastroenterol. 2017. PMID: 28932079 Free PMC article. Review.

4

Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.

Pokorny AMJ, Chin VT, Nagrial AM, Yip D, Chantrill LA. Pokorny AMJ, et al. Intern Med J. 2018 Jun;48(6):637-644. doi: 10.1111/imj.13810. Intern Med J. 2018. PMID: 29898269 Review.

5

Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.

Ur Rehman SS, Lim K, Wang-Gillam A. Ur Rehman SS, et al. Expert Rev Anticancer Ther. 2016 May;16(5):485-92. doi: 10.1080/14737140.2016.1174581. Epub 2016 Apr 22. Expert Rev Anticancer Ther. 2016. PMID: 27043737 Review.

6

Perspectives in the treatment of pancreatic adenocarcinoma.

Cid-Arregui A, Juarez V. Cid-Arregui A, et al. World J Gastroenterol. 2015 Aug 21;21(31):9297-316. doi: 10.3748/wjg.v21.i31.9297. World J Gastroenterol. 2015. PMID: 26309356 Free PMC article. Review.

7

Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.

Javed MA, Beyer G, Le N, Vinci A, Wong H, Palmer D, Morgan RD, Lamarca A, Hubner RA, Valle JW, Alam S, Chowdhury S, Ma YT, Archibugi L, Capurso G, Maisonneuve P, Neesse A, Sund M, Schober M, Krug S. Javed MA, et al. Pancreatology. 2019 Jan;19(1):97-104. doi: 10.1016/j.pan.2018.10.003. Epub 2018 Oct 15. Pancreatology. 2019. PMID: 30529068

8

Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.

Sclafani F, Iyer R, Cunningham D, Starling N. Sclafani F, et al. Crit Rev Oncol Hematol. 2015 Sep;95(3):318-36. doi: 10.1016/j.critrevonc.2015.03.008. Epub 2015 Apr 15. Crit Rev Oncol Hematol. 2015. PMID: 25921418 Review.

9

Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.

Lemstrova R, Melichar B, Mohelnikova-Duchonova B. Lemstrova R, et al. Cancer Chemother Pharmacol. 2016 Dec;78(6):1101-1111. doi: 10.1007/s00280-016-3058-y. Epub 2016 Jun 1. Cancer Chemother Pharmacol. 2016. PMID: 27250969 Review.

10

Prognostic and predictive markers in pancreatic adenocarcinoma.

Le N, Sund M, Vinci A; GEMS collaborating group of Pancreas 2000. Le N, et al. Dig Liver Dis. 2016 Mar;48(3):223-30. doi: 10.1016/j.dld.2015.11.001. Epub 2015 Nov 14. Dig Liver Dis. 2016. PMID: 26769569 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

85 results

Results by year